doi: 10.1016/j.intimp.2024.113426 73 MoldogazievaNTMokhosoevIMMelnikovaTIPorozovYBTerentievAA
Compared with patients who did not take obesity medication, patients taking semaglutide 2.4 mg lost 15.7 kg (34.6 pounds) more on average
They frequently work effectively in tandem with more activity and better dietary adjustments to enhance general health and wellness
This data-driven approach ensures your dosing planwhether taken on schedule or occasionally shiftedaligns with your unique metabolic profile and weight loss goals
Longer-term safety questions including effects on the pancreas, thyroid, gallbladder, and cardiovascular system remain under investigation in ongoing Phase 3 trials
However, another study revealed that increased polyamines promoted tumor growth and progression, and inhibition of polyamine could serve as a therapeutic strategy for renal cancer (Ochocki et al., 2018)